Official UK procurement notice
NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives
Authority: NHS England (Central government)
What is being bought
Published requirement descriptionProject title: NHS England procurement for the supply of Pan-genotypic Direct Acting Antiviral (DAA) Hepatitis C treatments and the provision of Hepatitis C elimination initiatives commencing 1st April 2026
Offer reference number: CM/TNS/25/5737
Period of framework: 1 April 2026 to 31 March 2028 with an option or options to extend (at the Authority's discretion) for a period or periods up to a total of 24 months.
CPV: Pharmaceutical products
How this framework works
From the published notice- Type
- Open framework
- Call-offs
- every call-off is a further competition among the appointed suppliers
- Bids received
- 2 bids received · 2 suppliers appointed
- Framework period
- 2 yrs · up to 4 yrs from 1 Apr 2026
- Buyer regions
- UKC, UKD, UKE, UKF, UKG, UKH, UKI, UKJ, UKK
Who may buy through it
See purchasing points list in tender document set
Published description of the framework
Please refer to the ITO documents for the Operation description
The lotProcurement structure
single lot · value publishedLot #1AwardedRenewalPublished value£160,000,000
What it takes to wini
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
Evaluation split and conditions of participation as published; the tender pack may add morei
How this buyer will score bids.
The evaluation criteria and weights exactly as published on the notice, grouped by family (price, quality, social value and so on).
- Price is not the only award criterion: Price is not the only award criterion and all criteria are stated in the procurement documentation
- “NHS England procurement for the supply of Pan-genotypic Direct Acting…” is a framework: the contest is a place on its panel, not a single contract: each call-off is a further competition, so the pricing contest starts after appointment.
Procedure terms & legal framework
From the official record- Procedure method
- Open procedure
- Legal basis
- UKPGA · 2023/54 Procurement Act 2023
- Procurement category
- Goods
- Notice status
- Awarded
- Procurement threshold
- Above threshold (FTS publication)
- Regulatory regime
- Standard
- Commercial structure
- Framework agreement
- Who may use the vehicle
- See purchasing points list in tender document set
- Competition type
- Competitive procedure
- GPA / WTO covered
- Yes (GPA)
- Recurring procurement
- Unspecified in notice
- First published
- 17 Oct 2025, 16:37 BST
- Last source update
- 7 Apr 2026, 16:16 BST
- Award evaluation window
- Submission end – 13 Feb 2026
- Authority reference
CM/TNS/25/5737- FTS notice number
2025/S 000-085570- Latest notice
- Contract details notice (UK7)
- Classification (CPV)
- Delivery area
- Official registry OCID
ocds-h6vhtk-05cf3bFind a Tender
How it was run
Official notice- Appointment period ends
- 6 Feb 2026, 13:00 GMT
- Clarification deadline
- 30 Jan 2026, 17:00 GMT
- Submission channel
- Official e-sourcing portal
- Electronic submission
- Allowed
- Accepted languages
- en
The procurement documents are available for unrestricted and full direct access, free of charge at health-family.force.com/s/Welcome ↗
Additional information may be obtained
from the abovementioned address.
Tenders must be submitted to the
abovementioned address.
Timeline
17 Oct 2025 → 7 Apr 2026 · 11 dates- Planning notice published363 days ago17 Oct 2025, 16:37 BST
- Market engagement335 days ago14 Nov 2025, 23:59 GMT
NHS England is seeking to engage with suppliers of Hepatitis C treatments. Interested suppliers will be invited to a virtual PME meeting to be held w/c 3rd or 10th November 2025.
The purpose of these sessions is to update suppliers regarding timelines and to discuss product details, proposed framework period, tender structure, and KPl's.
Please contact [email protected] to register your interest in tendering for this framework.
- Next notice expected318 days ago1 Dec 2025, 23:59 GMT
- Tender notice published297 days ago22 Dec 2025, 16:55 GMT
- Clarification questions by258 days ago30 Jan 2026, 17:00 GMT
- Admission / appointment period ends251 days ago · period end, not a bid countdown6 Feb 2026, 13:00 GMT
- Award decision expected by244 days ago13 Feb 2026, 23:59 GMT
- Assessment summaries sent232 days ago26 Feb 2026
- Standstill ends220 days ago9 Mar 2026, 23:59 GMT
- Contract starts198 days ago1 Apr 2026, 00:00 BST
- Latest notice published191 days ago7 Apr 2026, 16:16 BST
Notice history
11 events · 5 releases on Find a Tender · since 17 Oct 2025- Preliminary market engagement notice published17 Oct 2025, 16:37 BSTUK2
- Tender notice published22 Dec 2025, 16:55 GMTUK4
- Status changed to active22 Dec 2025, 16:55 GMT
- Procurement method changed22 Dec 2025, 16:55 GMT
- Deadline published: 30 Jan 2026, 13:00 GMT22 Dec 2025, 16:55 GMT
- Tender notice published28 Jan 2026, 12:58 GMTUK4
- Deadline moved to 6 Feb 2026, 13:00 GMT28 Jan 2026, 12:58 GMT+7 days · was 30 Jan 2026, 13:00 GMT
- Contract award notice published26 Feb 2026, 15:59 GMTUK6
- Status changed to complete26 Feb 2026, 15:59 GMT
- Contract signature expected13 Mar 2026, 23:59 GMTscheduled
- Contract details notice published7 Apr 2026, 16:16 BSTUK7
Published amendments (1)
Updated tender document set - revised Doc 3 and new doc 5c
Routine re-releases (5)
- 2025-12: 1 release · 22 Dec 2025
- 2025-10: 1 release · 17 Oct 2025
Commercial outcome & contract awards
Published awards, contracts and bid statistics, not a forecast| Awarded to | Value | Date | Status |
|---|---|---|---|
| Abbvie Ltd, Gilead Sciences LtdNHS England procurement for the supply of pangenotypic Hepatitis C treatments and the provision of Hepatitis C elimination initiatives1 Apr 2026 – 31 Mar 2028 · up to 31 Mar 2030Extensions: Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. · Options: Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months. | £160,000,000 | 25 Feb 2026 | Awarded |
Contracts
NHS England procurement for the supply of pangenotypic Hepatitis C treatments and the provision of Hepatitis C elimination initiatives · Abbvie Ltd, Gilead Sciences Ltd
- Signed
- 11 Mar 2026
- Value
- £160,000,000
- Period
- 1 Apr 2026 – 31 Mar 2028 · up to 31 Mar 2030 with extensions
- Status
- active
- Extensions
- Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
- Options
- Option or options to extend (at the Authority’s discretion) for a period or periods up to a total of 24 months.
Bid statistics published by the authority
| Bids | SME | VCSE | Valid bid range |
|---|---|---|---|
| 2final-stage tenders | 0 | 0 | — |
Who bid
- wonAbbvie Ltd · South East England
- wonGilead Sciences Limited · Greater London
Bidders as named on the Procurement Act 2023 award notice. “Won” means the bidder holds an award on this notice.
Contracting authority & participating public bodies
Framework contractors & participating bidders
2 commercial parties on the notice- Abbvie LtdFramework contractor
- Gilead Sciences LimitedFramework contractor
Official documents & specifications (9)
Official links; attachments are not copiedTender pack and attachments
- Bidding documents and specifications
- Signed contract
- Signed contract
- Bidding documents and specifications Full Tender Document set
Notices published for this procedure
- Contract details notice Contract details notice on Find a Tender
- Contract award notice Contract award notice on Find a Tender
- Tender notice Tender notice on Find a Tender
- Tender notice Tender notice on Find a Tender
- Preliminary market engagement notice Preliminary market engagement notice on Find a Tender